Represented Marrone Bio Innovations, Inc. in its $244 million acquisition by Bioceres Crop Solutions Corp. in a stock-for-stock merger.
Represented Temasek Holdings Pte Ltd. in connection with a joint venture with Bayer to create Unfold Bio, Inc., a new venture to focus on innovation in vegetable varieties with the goal of lifting the vertical farming space to the next level of quality, efficiency and sustainability. We also assisted Temasek in the initial Series A financing and negotiation of a licensing agreement between Bayer and Unfold Bio.
Represented SoftBank Group and SoftBank Vision Fund in over $2 billion of nine-figure transactions, including investments in online lending platform Kabbage, Inc., the autonomous vehicle company Nauto, AI company Brain Corporation and infectious disease blood tester Karius, Inc.
Represented Singapore investment fund Temasek in its $800 million investment in Verily Life Sciences, Alphabet/Google's life sciences division, and multiple investments in the agtech space.
Represented Intel Corporation in its $740 million acquisition of an 18% stake in Cloudera, Inc.
Represented Visa Ventures in nearly two dozen fintech investments in the U.S., Latin America, Europe, Africa and Asia, including Plaid, GoodData, Flutterwave, and others.
Represented Marrone Bio Innovations, Inc. (NASDAQ: MBII), a leading provider of bio-based pest-management and plant health products, as issuer's counsel in an initial public offering, follow-on common stock offerings, private placements, debt refinance and warrant restructure transactions for nearly $300 million.
Represented Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a leading developer of exoskeleton solutions that amplify human potential for medical and industrial uses, as issuer's counsel in multiple public and private stock and warrant offerings.
Represented Temasek in its investment of up to $150 million in biosimilar therapeutics company Coherus, Inc. (NASDAQ: CHRS), in a private placement transition.
Represented Catalyst Biosciences, Inc. (NASDAQ: CBIO) in its IPO/reverse merger with Targacept and a $20.7 million underwritten public offering.